Anti‐ribosomal P protein antibodies in patients with systemic lupus erythematosus is associated with hyperferritinemia
Aim Anti‐ribosomal P protein antibodies (anti‐ribo P) have been reported as one of the specific autoantibodies in patients with systemic lupus erythematosus (SLE) and has been demonstrated to bind and activate macrophages in vitro. Clinically, hyperferritinemia has been known to be a biomarker for m...
Gespeichert in:
| Veröffentlicht in: | International journal of rheumatic diseases 2022-01, Vol.25 (1), p.70-75 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 75 |
|---|---|
| container_issue | 1 |
| container_start_page | 70 |
| container_title | International journal of rheumatic diseases |
| container_volume | 25 |
| creator | Arinuma, Yoshiyuki Hirohata, Shunsei Isayama, Takuya Hasegawa, Yasuhiro Muramatsu, Takumi Kondo, Junichi Kanayama, Yoshiro Ino, Kazuma Matsueda, Yu Oku, Kenji Yamaoka, Kunihiro |
| description | Aim
Anti‐ribosomal P protein antibodies (anti‐ribo P) have been reported as one of the specific autoantibodies in patients with systemic lupus erythematosus (SLE) and has been demonstrated to bind and activate macrophages in vitro. Clinically, hyperferritinemia has been known to be a biomarker for macrophage activation. The aim of this study is to clarify the relationship of anti‐ribo P and clinical characteristics and biomarkers including serum ferritin in patients with SLE.
Methods
Clinical parameters and laboratory data were measured in patients with active SLE (N = 127) in our university hospital. The risk factors affected by anti‐ribo P were retrospectively calculated by logistic regression analysis, and the correlation of anti‐ribo P and clinical factors was demonstrated.
Results
Anti‐ribo P was significantly elevated in active SLE compared to non‐SLE diseases (P |
| doi_str_mv | 10.1111/1756-185X.14245 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2599181794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2615866469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3255-2d5098788d41b4a3c2d06a2493b47a782dc9bb0c1a010fb67bb043854ff1daa23</originalsourceid><addsrcrecordid>eNqFkcFu3CAURVHUKDOdZp1dhdRNNpMABmyWo6hJKo3UWbRSdwjbWENkG5eHlXqXT8g35kvCxOksuikbuLzzruBdhC4ouaJpXdNcyDUtxK8ryhkXJ2h5vPlwPHO6QB8BHgiRNJP5GVpkPFdSSrVEfzZ9dC9Pz8GVHnxnWrzDQ_DRuh6bVCp97SzgpAYTne0j4EcX9xgmiLZzFW7HYQRswxT3tjPRQ1IOsAHwlTPR1jO_nwYbGhuCi65PjeYTOm1MC_b8fV-hn7dff9zcr7ff777dbLbrKmNCrFktiCryoqg5LbnJKlYTaRhXWclzkxesrlRZkooaQklTyjwJnhWCNw2tjWHZCl3OvulXv0cLUXcOKtu2prd-BM2EUrSgueIJ_fIP-uDH0KfXaSapKKTkUiXqeqaq4AGCbfQQXGfCpCnRh1D0Yez6EIF-CyV1fH73HcvO1kf-bwoJEDPw6Fo7_c9Pb3bb2fgVNjKaDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2615866469</pqid></control><display><type>article</type><title>Anti‐ribosomal P protein antibodies in patients with systemic lupus erythematosus is associated with hyperferritinemia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Arinuma, Yoshiyuki ; Hirohata, Shunsei ; Isayama, Takuya ; Hasegawa, Yasuhiro ; Muramatsu, Takumi ; Kondo, Junichi ; Kanayama, Yoshiro ; Ino, Kazuma ; Matsueda, Yu ; Oku, Kenji ; Yamaoka, Kunihiro</creator><creatorcontrib>Arinuma, Yoshiyuki ; Hirohata, Shunsei ; Isayama, Takuya ; Hasegawa, Yasuhiro ; Muramatsu, Takumi ; Kondo, Junichi ; Kanayama, Yoshiro ; Ino, Kazuma ; Matsueda, Yu ; Oku, Kenji ; Yamaoka, Kunihiro</creatorcontrib><description>Aim
Anti‐ribosomal P protein antibodies (anti‐ribo P) have been reported as one of the specific autoantibodies in patients with systemic lupus erythematosus (SLE) and has been demonstrated to bind and activate macrophages in vitro. Clinically, hyperferritinemia has been known to be a biomarker for macrophage activation. The aim of this study is to clarify the relationship of anti‐ribo P and clinical characteristics and biomarkers including serum ferritin in patients with SLE.
Methods
Clinical parameters and laboratory data were measured in patients with active SLE (N = 127) in our university hospital. The risk factors affected by anti‐ribo P were retrospectively calculated by logistic regression analysis, and the correlation of anti‐ribo P and clinical factors was demonstrated.
Results
Anti‐ribo P was significantly elevated in active SLE compared to non‐SLE diseases (P < .0001). Sensitivity and the specificity of anti‐ribo P in patients with SLE were 32.0% and 99.3%, respectively. Patients positive for anti‐ribo P had the highest risk for elevated serum ferritin (odds ratio: 8.432). Accordingly, anti‐ribo P positive patients had significantly elevated serum ferritin compared to negative patients (P = .024). A significant positive correlation was observed between the anti‐ribo P titer and the serum ferritin level (r2 = .07, t = 5.22, P = .0081), but not serum interleukin (IL)‐6 in SLE patients.
Conclusion
The presence of anti‐ribo P is a risk factor for higher ferritin levels that is independent of systemic inflammation regulated by IL‐6. We speculate that anti‐ribo P could be directly associated with macrophage activation leading to hyperferritinemia in patients with SLE.</description><identifier>ISSN: 1756-1841</identifier><identifier>EISSN: 1756-185X</identifier><identifier>DOI: 10.1111/1756-185X.14245</identifier><identifier>PMID: 34796669</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Antibodies, Antinuclear - blood ; anti‐ribosomal P protein antibody ; Autoantibodies ; autoantibody ; Biomarkers ; Biomarkers - blood ; Cell activation ; Female ; Ferritin ; Ferritins - blood ; Humans ; Hyperferritinemia - blood ; Hyperferritinemia - diagnosis ; Lupus ; Lupus Erythematosus, Systemic - blood ; Lupus Erythematosus, Systemic - immunology ; macrophage activation ; Macrophages ; Male ; Middle Aged ; Patients ; Risk Factors ; Systemic lupus erythematosus</subject><ispartof>International journal of rheumatic diseases, 2022-01, Vol.25 (1), p.70-75</ispartof><rights>2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd</rights><rights>2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.</rights><rights>International Journal of Rheumatic Diseases © 2022 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3255-2d5098788d41b4a3c2d06a2493b47a782dc9bb0c1a010fb67bb043854ff1daa23</cites><orcidid>0000-0003-1305-991X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1756-185X.14245$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1756-185X.14245$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34796669$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arinuma, Yoshiyuki</creatorcontrib><creatorcontrib>Hirohata, Shunsei</creatorcontrib><creatorcontrib>Isayama, Takuya</creatorcontrib><creatorcontrib>Hasegawa, Yasuhiro</creatorcontrib><creatorcontrib>Muramatsu, Takumi</creatorcontrib><creatorcontrib>Kondo, Junichi</creatorcontrib><creatorcontrib>Kanayama, Yoshiro</creatorcontrib><creatorcontrib>Ino, Kazuma</creatorcontrib><creatorcontrib>Matsueda, Yu</creatorcontrib><creatorcontrib>Oku, Kenji</creatorcontrib><creatorcontrib>Yamaoka, Kunihiro</creatorcontrib><title>Anti‐ribosomal P protein antibodies in patients with systemic lupus erythematosus is associated with hyperferritinemia</title><title>International journal of rheumatic diseases</title><addtitle>Int J Rheum Dis</addtitle><description>Aim
Anti‐ribosomal P protein antibodies (anti‐ribo P) have been reported as one of the specific autoantibodies in patients with systemic lupus erythematosus (SLE) and has been demonstrated to bind and activate macrophages in vitro. Clinically, hyperferritinemia has been known to be a biomarker for macrophage activation. The aim of this study is to clarify the relationship of anti‐ribo P and clinical characteristics and biomarkers including serum ferritin in patients with SLE.
Methods
Clinical parameters and laboratory data were measured in patients with active SLE (N = 127) in our university hospital. The risk factors affected by anti‐ribo P were retrospectively calculated by logistic regression analysis, and the correlation of anti‐ribo P and clinical factors was demonstrated.
Results
Anti‐ribo P was significantly elevated in active SLE compared to non‐SLE diseases (P < .0001). Sensitivity and the specificity of anti‐ribo P in patients with SLE were 32.0% and 99.3%, respectively. Patients positive for anti‐ribo P had the highest risk for elevated serum ferritin (odds ratio: 8.432). Accordingly, anti‐ribo P positive patients had significantly elevated serum ferritin compared to negative patients (P = .024). A significant positive correlation was observed between the anti‐ribo P titer and the serum ferritin level (r2 = .07, t = 5.22, P = .0081), but not serum interleukin (IL)‐6 in SLE patients.
Conclusion
The presence of anti‐ribo P is a risk factor for higher ferritin levels that is independent of systemic inflammation regulated by IL‐6. We speculate that anti‐ribo P could be directly associated with macrophage activation leading to hyperferritinemia in patients with SLE.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Antinuclear - blood</subject><subject>anti‐ribosomal P protein antibody</subject><subject>Autoantibodies</subject><subject>autoantibody</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Cell activation</subject><subject>Female</subject><subject>Ferritin</subject><subject>Ferritins - blood</subject><subject>Humans</subject><subject>Hyperferritinemia - blood</subject><subject>Hyperferritinemia - diagnosis</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - blood</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>macrophage activation</subject><subject>Macrophages</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Risk Factors</subject><subject>Systemic lupus erythematosus</subject><issn>1756-1841</issn><issn>1756-185X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu3CAURVHUKDOdZp1dhdRNNpMABmyWo6hJKo3UWbRSdwjbWENkG5eHlXqXT8g35kvCxOksuikbuLzzruBdhC4ouaJpXdNcyDUtxK8ryhkXJ2h5vPlwPHO6QB8BHgiRNJP5GVpkPFdSSrVEfzZ9dC9Pz8GVHnxnWrzDQ_DRuh6bVCp97SzgpAYTne0j4EcX9xgmiLZzFW7HYQRswxT3tjPRQ1IOsAHwlTPR1jO_nwYbGhuCi65PjeYTOm1MC_b8fV-hn7dff9zcr7ff777dbLbrKmNCrFktiCryoqg5LbnJKlYTaRhXWclzkxesrlRZkooaQklTyjwJnhWCNw2tjWHZCl3OvulXv0cLUXcOKtu2prd-BM2EUrSgueIJ_fIP-uDH0KfXaSapKKTkUiXqeqaq4AGCbfQQXGfCpCnRh1D0Yez6EIF-CyV1fH73HcvO1kf-bwoJEDPw6Fo7_c9Pb3bb2fgVNjKaDA</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Arinuma, Yoshiyuki</creator><creator>Hirohata, Shunsei</creator><creator>Isayama, Takuya</creator><creator>Hasegawa, Yasuhiro</creator><creator>Muramatsu, Takumi</creator><creator>Kondo, Junichi</creator><creator>Kanayama, Yoshiro</creator><creator>Ino, Kazuma</creator><creator>Matsueda, Yu</creator><creator>Oku, Kenji</creator><creator>Yamaoka, Kunihiro</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1305-991X</orcidid></search><sort><creationdate>202201</creationdate><title>Anti‐ribosomal P protein antibodies in patients with systemic lupus erythematosus is associated with hyperferritinemia</title><author>Arinuma, Yoshiyuki ; Hirohata, Shunsei ; Isayama, Takuya ; Hasegawa, Yasuhiro ; Muramatsu, Takumi ; Kondo, Junichi ; Kanayama, Yoshiro ; Ino, Kazuma ; Matsueda, Yu ; Oku, Kenji ; Yamaoka, Kunihiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3255-2d5098788d41b4a3c2d06a2493b47a782dc9bb0c1a010fb67bb043854ff1daa23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Antinuclear - blood</topic><topic>anti‐ribosomal P protein antibody</topic><topic>Autoantibodies</topic><topic>autoantibody</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Cell activation</topic><topic>Female</topic><topic>Ferritin</topic><topic>Ferritins - blood</topic><topic>Humans</topic><topic>Hyperferritinemia - blood</topic><topic>Hyperferritinemia - diagnosis</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - blood</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>macrophage activation</topic><topic>Macrophages</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Risk Factors</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arinuma, Yoshiyuki</creatorcontrib><creatorcontrib>Hirohata, Shunsei</creatorcontrib><creatorcontrib>Isayama, Takuya</creatorcontrib><creatorcontrib>Hasegawa, Yasuhiro</creatorcontrib><creatorcontrib>Muramatsu, Takumi</creatorcontrib><creatorcontrib>Kondo, Junichi</creatorcontrib><creatorcontrib>Kanayama, Yoshiro</creatorcontrib><creatorcontrib>Ino, Kazuma</creatorcontrib><creatorcontrib>Matsueda, Yu</creatorcontrib><creatorcontrib>Oku, Kenji</creatorcontrib><creatorcontrib>Yamaoka, Kunihiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arinuma, Yoshiyuki</au><au>Hirohata, Shunsei</au><au>Isayama, Takuya</au><au>Hasegawa, Yasuhiro</au><au>Muramatsu, Takumi</au><au>Kondo, Junichi</au><au>Kanayama, Yoshiro</au><au>Ino, Kazuma</au><au>Matsueda, Yu</au><au>Oku, Kenji</au><au>Yamaoka, Kunihiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti‐ribosomal P protein antibodies in patients with systemic lupus erythematosus is associated with hyperferritinemia</atitle><jtitle>International journal of rheumatic diseases</jtitle><addtitle>Int J Rheum Dis</addtitle><date>2022-01</date><risdate>2022</risdate><volume>25</volume><issue>1</issue><spage>70</spage><epage>75</epage><pages>70-75</pages><issn>1756-1841</issn><eissn>1756-185X</eissn><abstract>Aim
Anti‐ribosomal P protein antibodies (anti‐ribo P) have been reported as one of the specific autoantibodies in patients with systemic lupus erythematosus (SLE) and has been demonstrated to bind and activate macrophages in vitro. Clinically, hyperferritinemia has been known to be a biomarker for macrophage activation. The aim of this study is to clarify the relationship of anti‐ribo P and clinical characteristics and biomarkers including serum ferritin in patients with SLE.
Methods
Clinical parameters and laboratory data were measured in patients with active SLE (N = 127) in our university hospital. The risk factors affected by anti‐ribo P were retrospectively calculated by logistic regression analysis, and the correlation of anti‐ribo P and clinical factors was demonstrated.
Results
Anti‐ribo P was significantly elevated in active SLE compared to non‐SLE diseases (P < .0001). Sensitivity and the specificity of anti‐ribo P in patients with SLE were 32.0% and 99.3%, respectively. Patients positive for anti‐ribo P had the highest risk for elevated serum ferritin (odds ratio: 8.432). Accordingly, anti‐ribo P positive patients had significantly elevated serum ferritin compared to negative patients (P = .024). A significant positive correlation was observed between the anti‐ribo P titer and the serum ferritin level (r2 = .07, t = 5.22, P = .0081), but not serum interleukin (IL)‐6 in SLE patients.
Conclusion
The presence of anti‐ribo P is a risk factor for higher ferritin levels that is independent of systemic inflammation regulated by IL‐6. We speculate that anti‐ribo P could be directly associated with macrophage activation leading to hyperferritinemia in patients with SLE.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34796669</pmid><doi>10.1111/1756-185X.14245</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-1305-991X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-1841 |
| ispartof | International journal of rheumatic diseases, 2022-01, Vol.25 (1), p.70-75 |
| issn | 1756-1841 1756-185X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2599181794 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Antibodies, Antinuclear - blood anti‐ribosomal P protein antibody Autoantibodies autoantibody Biomarkers Biomarkers - blood Cell activation Female Ferritin Ferritins - blood Humans Hyperferritinemia - blood Hyperferritinemia - diagnosis Lupus Lupus Erythematosus, Systemic - blood Lupus Erythematosus, Systemic - immunology macrophage activation Macrophages Male Middle Aged Patients Risk Factors Systemic lupus erythematosus |
| title | Anti‐ribosomal P protein antibodies in patients with systemic lupus erythematosus is associated with hyperferritinemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T19%3A04%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti%E2%80%90ribosomal%20P%20protein%20antibodies%20in%20patients%20with%20systemic%20lupus%20erythematosus%20is%20associated%20with%20hyperferritinemia&rft.jtitle=International%20journal%20of%20rheumatic%20diseases&rft.au=Arinuma,%20Yoshiyuki&rft.date=2022-01&rft.volume=25&rft.issue=1&rft.spage=70&rft.epage=75&rft.pages=70-75&rft.issn=1756-1841&rft.eissn=1756-185X&rft_id=info:doi/10.1111/1756-185X.14245&rft_dat=%3Cproquest_cross%3E2615866469%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2615866469&rft_id=info:pmid/34796669&rfr_iscdi=true |